We are delighted to announce that the Indian Patent Office has granted a patent (Ref no. 351940) for our groundbreaking nanoparticle-based MRI contrast agent technology.
This patent protects our novel approach to developing safer contrast agents that eliminate the risk of Nephrogenic Systemic Fibrosis (NSF) associated with traditional gadolinium-based contrast agents. Our iron-based formulation is specifically designed for renal impaired patients where GBCA is banned by FDA.
This achievement reinforces our commitment to innovation and patient safety. We continue to work towards bringing this life-saving technology to market.